Difference between revisions of "HAN5:Volunteer Assignments and Opportunities"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
VisualWikitext
[checked revision][checked revision]
Line 6: Line 6:
  
 
To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
 
To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
−
 
−
<br />
 
 
{| class="wikitable" style="margin:auto"
 
{| class="wikitable" style="margin:auto"
 
|+<big>WHO Classification of Head and Neck Tumours (5th Edition) Content</big>
 
|+<big>WHO Classification of Head and Neck Tumours (5th Edition) Content</big>
Line 19: Line 17:
 
!'''Notes'''
 
!'''Notes'''
 
|-
 
|-
 +
|[[GTS5:Hereditary_papillary_renal_carcinoma_(MET)|Hereditary papillary renal carcinoma (MET)]]
 +
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Multiple_endocrine_neoplasia_type_2_(RET)|Multiple endocrine neoplasia type 2 (RET)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 29: Line 39:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Juvenile_polyposis_syndrome_(BMPR1A,_SMAD4)|Juvenile polyposis syndrome (BMPR1A, SMAD4)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 38: Line 50:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Hereditary_neuroblastoma_(ALK,_PHOX2B)|Hereditary neuroblastoma (ALK, PHOX2B)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 47: Line 61:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Encephalocraniocutaneous_lipomatosis_(FGFR1)|Encephalocraniocutaneous lipomatosis (FGFR1)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 56: Line 72:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Glucagon_cell_hyperplasia_and_neoplasia_(GCGR)|Glucagon cell hyperplasia and neoplasia (GCGR)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 65: Line 83:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:McCune-Albright_syndrome_(GNAS)|McCune-Albright syndrome (GNAS)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 74: Line 94:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Sturge-Weber_syndrome_(GNAQ)|Sturge-Weber syndrome (GNAQ)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 83: Line 105:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Neurofibromatosis_type_1_(NF1)|Neurofibromatosis type 1 (NF1)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 92: Line 116:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:NF2-related_schwannomatosis_(NF2)|NF2-related schwannomatosis (NF2)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 101: Line 127:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Costello_syndrome_(HRAS)|Costello syndrome (HRAS)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 110: Line 138:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Noonan_syndrome_(Various_genes)|Noonan syndrome (Various genes)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 119: Line 149:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Schimmelpenning-Feuerstein-Mims_(HRAS,_KRAS)|Schimmelpenning-Feuerstein-Mims (HRAS, KRAS)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 128: Line 160:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Carney_complex_(PRKAR1A,_PDE8B,_PDE11A)|Carney complex (PRKAR1A, PDE8B, PDE11A)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 137: Line 171:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:PROS_syndrome_(PIK3CA)|PROS syndrome (PIK3CA)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 146: Line 182:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Familial_adenomatous_polyposis_(APC)|Familial adenomatous polyposis (APC)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 155: Line 193:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Gastric_Adenocarcinoma_and_Proximal_Polyposis_of_Stomach_-_GAPPS_(APC_promoter)|Gastric Adenocarcinoma and Proximal Polyposis of Stomach - GAPPS (APC promoter)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 164: Line 204:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:AXIN2-associated_polyposis_(AXIN2)|AXIN2-associated polyposis (AXIN2)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 173: Line 215:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Serrated_polyposis_(RNF43)|Serrated polyposis (RNF43)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 182: Line 226:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:WT1_related_tumour_predisposition_syndrome_(WT1)|WT1 related tumour predisposition syndrome (WT1)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 191: Line 237:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:WAGR_syndrome_(WT1)|WAGR syndrome (WT1)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 200: Line 248:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Multiple_endocrine_neoplasia_type_1_(MEN1)|Multiple endocrine neoplasia type 1 (MEN1)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 209: Line 259:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Peutz-Jeghers_syndrome_(STK11)|Peutz-Jeghers syndrome (STK11)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 218: Line 270:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Hereditary_gastric_and_breast_cancer_syndrome_(CDH1,_CTNNA1)|Hereditary gastric and breast cancer syndrome (CDH1, CTNNA1)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 227: Line 281:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Hereditary_mixed_polyposis_syndrome_(GREM1)|Hereditary mixed polyposis syndrome (GREM1)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 236: Line 292:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Naevoid_basal_cell_carcinoma_syndrome_-_Gorlin_syndrome_(PTCH1,_SUFU,_GPR161)|Naevoid basal cell carcinoma syndrome - Gorlin syndrome (PTCH1, SUFU, GPR161)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 245: Line 303:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:SMO-related_Curry-Jones_syndrome_(SMO)|SMO-related Curry-Jones syndrome (SMO)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 254: Line 314:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:ELP1-related_medulloblastoma_predisposition_syndrome(ELP1)|ELP1-related medulloblastoma predisposition syndrome(ELP1)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 263: Line 325:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Osteochondromatosis_(EXT1,_EXT2)|Osteochondromatosis (EXT1, EXT2)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 272: Line 336:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Brooke-Spiegler_syndrome_(CYLD)|Brooke-Spiegler syndrome (CYLD)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 281: Line 347:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Tuberous_sclerosis_(TSC1,_TSC1)|Tuberous sclerosis (TSC1, TSC1)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 290: Line 358:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:PTEN_hamartoma_tumour_syndrome_(PTEN)|PTEN hamartoma tumour syndrome (PTEN)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 299: Line 369:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Activated_Phosphatidylinositol-3-OH_kinase_&#948;_Syndrome_-_APDS_(PIK3CD)|Activated Phosphatidylinositol-3-OH kinase &#948; Syndrome - APDS (PIK3CD)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 308: Line 380:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Multiple_endocrine_neoplasia_type_5,_MAX_related_tumours_(MAX)|Multiple endocrine neoplasia type 5, MAX related tumours (MAX)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 317: Line 391:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:MAFA-related_familial_insulinomatosis_(MAFA)|MAFA-related familial insulinomatosis (MAFA)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 326: Line 402:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Birt-Hogg-Dube_syndrome_(FLCN)|Birt-Hogg-Dube syndrome (FLCN)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 335: Line 413:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Familial_chordoma_(TBXT)|Familial chordoma (TBXT)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 344: Line 424:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Hyperparathyroidism_jaw_tumour_syndrome_(CDC73)|Hyperparathyroidism jaw tumour syndrome (CDC73)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 353: Line 435:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Von_Hippel-Lindau_syndrome_(VHL)|Von Hippel-Lindau syndrome (VHL)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 362: Line 446:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:SDH-deficient_tumour_syndrome_-_Hereditary_phaeochromocytoma-paraganglioma_syndromes_(SDHA,_SDHB,_SDHC,_SDHD,_SDHAF2)|SDH-deficient tumour syndrome - Hereditary phaeochromocytoma-paraganglioma syndromes (SDHA, SDHB, SDHC, SDHD, SDHAF2)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 371: Line 457:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Hereditary_leiomyomatosis_and_renal_cell_carcinoma_syndrome_(FH)|Hereditary leiomyomatosis and renal cell carcinoma syndrome (FH)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 380: Line 468:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Hereditary_tyrosinaemia_type_1_(FAH)|Hereditary tyrosinaemia type 1 (FAH)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 389: Line 479:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Li-Fraumeni_syndrome_(TP53)|Li-Fraumeni syndrome (TP53)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 398: Line 490:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Retinoblastoma_syndrome_(RB1)|Retinoblastoma syndrome (RB1)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 407: Line 501:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Multiple_endocrine_neoplasia_type_4_(CDKN1B)|Multiple endocrine neoplasia type 4 (CDKN1B)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 416: Line 512:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:CDKN2A-related_tumour_predisposition_syndrome_(CDKN2A)|CDKN2A-related tumour predisposition syndrome (CDKN2A)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 425: Line 523:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:CDK4-related_melanoma_predisposition_syndrome_(CDK4)|CDK4-related melanoma predisposition syndrome (CDK4)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 434: Line 534:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Autoimmune_lymphoproliferative_syndrome_(FAS)|Autoimmune lymphoproliferative syndrome (FAS)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 443: Line 545:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Lynch_Syndrome_(MLH1,_PMS2,_MSH2,_MSH6)|Lynch Syndrome (MLH1, PMS2, MSH2, MSH6)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 452: Line 556:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Muir-Torre_syndrome_(MLH1,_PMS2,_MSH2,_MSH6)|Muir-Torre syndrome (MLH1, PMS2, MSH2, MSH6)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 461: Line 567:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Constitutional_mismatch_repair_deficiency_(CMMRD)_syndrome_(MLH1,_PMS2,_MSH2,_MSH6)|Constitutional mismatch repair deficiency (CMMRD) syndrome (MLH1, PMS2, MSH2, MSH6)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 470: Line 578:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:BRCA-related_cancer_predisposition_syndrome_(BRCA1,_BRCA2)|BRCA-related cancer predisposition syndrome (BRCA1, BRCA2)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 479: Line 589:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:PALB2-related_cancer_predisposition_syndrome_(PALB2)|PALB2-related cancer predisposition syndrome (PALB2)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 488: Line 600:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:RAD51-related_cancer_predisposition_syndrome_(RAD51C,_RAD51D)|RAD51-related cancer predisposition syndrome (RAD51C, RAD51D)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 497: Line 611:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Fanconi_anaemia_(FANC_genes)|Fanconi anaemia (FANC genes)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 506: Line 622:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:MUTYH-associated_polyposis_(MUTYH)|MUTYH-associated polyposis (MUTYH)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 515: Line 633:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:NTHL1-related_tumour_syndrome_(NTHL1)|NTHL1-related tumour syndrome (NTHL1)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 524: Line 644:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:MBD4-associated_neoplasia_syndrome_(MBD4)|MBD4-associated neoplasia syndrome (MBD4)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 533: Line 655:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Xeroderma_Pigmentosum|Xeroderma Pigmentosum]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 542: Line 666:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Ataxia-telangiectasia_syndrome_(ATM)|Ataxia-telangiectasia syndrome (ATM)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 551: Line 677:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:CHEK2-related_hereditary_(breast)_cancer_predisposition_syndrome_(CHEK2)|CHEK2-related hereditary (breast) cancer predisposition syndrome (CHEK2)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 560: Line 688:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Nijmegen_breakage_syndrome_(NBN)|Nijmegen breakage syndrome (NBN)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 569: Line 699:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Polymerase_proofreading-associated_polyposis_(POLD1,_POLE)|Polymerase proofreading-associated polyposis (POLD1, POLE)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 578: Line 710:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Bloom_syndrome_(BLM)|Bloom syndrome (BLM)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 587: Line 721:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Werner_syndrome_(WRN)|Werner syndrome (WRN)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 596: Line 732:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Rothmund-Thomson_syndrome_(ANAPC1,_RECQL4)|Rothmund-Thomson syndrome (ANAPC1, RECQL4)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 605: Line 743:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:DDX41-related_haematologic_tumour_predisposition_syndrome_(DDX41)|DDX41-related haematologic tumour predisposition syndrome (DDX41)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 614: Line 754:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Mosaic_variegated_aneuploidy_(BUB1B,_CEP57,_TRIP13,_BUB1,_BUB3)|Mosaic variegated aneuploidy (BUB1B, CEP57, TRIP13, BUB1, BUB3)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 623: Line 765:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Klinefelter_syndrome|Klinefelter syndrome]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 632: Line 776:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Turner_syndrome|Turner syndrome]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 641: Line 787:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Down_syndrome|Down syndrome]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 650: Line 798:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Dyskeratosis_congenita_(DKC1,_TERT,_TERC,_TINF2,_Other_IBMFS_genes)|Dyskeratosis congenita (DKC1, TERT, TERC, TINF2, Other IBMFS genes)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 659: Line 809:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:POT1_and_Shelterin-related_tumour_predisposition_syndrome_(POT1,_ACD,_TERF2IP,_TERT_promoter)|POT1 and Shelterin-related tumour predisposition syndrome (POT1, ACD, TERF2IP, TERT promoter)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 668: Line 820:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Beckwith-Wiedemann_spectrum_(IGF2;_CDKN1C)|Beckwith-Wiedemann spectrum (IGF2; CDKN1C)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 677: Line 831:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Enchondromatosis_(IDH1,_IDH2)|Enchondromatosis (IDH1, IDH2)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 686: Line 842:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Rhabdoid_tumour_predisposition_syndrome_(SMARCB1,_SMARCA4)|Rhabdoid tumour predisposition syndrome (SMARCB1, SMARCA4)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 695: Line 853:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Schwannomatosis_(SMARCB1,_LZTR1)|Schwannomatosis (SMARCB1, LZTR1)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 704: Line 864:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Clear_cell_meningioma_predisposition_syndrome_(SMARCE1)|Clear cell meningioma predisposition syndrome (SMARCE1)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 713: Line 875:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:Weaver_syndrome_(EZH2)|Weaver syndrome (EZH2)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 722: Line 886:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:DICER1-related_tumour_predisposition_syndrome_(DICER1)|DICER1-related tumour predisposition syndrome (DICER1)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 731: Line 897:
 
|
 
|
 
|-
 
|-
−
| ||Disease||
+
|[[GTS5:MicroRNA_processor_tumour_predisposition_syndromes_(DROSHA,_DGCR8)|MicroRNA processor tumour predisposition syndromes (DROSHA, DGCR8)]]
 +
|Disease
 +
|
 
|
 
|
 
|
 
|
Line 740: Line 908:
 
|
 
|
 
|-
 
|-
 +
|[[GTS5:Goldenhar_syndrome_(MYT1,_SF3B2)|Goldenhar syndrome (MYT1, SF3B2)]]
 +
|Disease
 +
|
 +
|
 +
|
 +
|
 +
|
 +
|
 
|
 
|
 +
|
 +
|-
 +
|[[GTS5:BAP1-related_tumour_predisposition_syndrome_(BAP1)|BAP1-related tumour predisposition syndrome (BAP1)]]
 
|Disease
 
|Disease
 
|
 
|

Revision as of 14:04, 25 February 2024

Welcome!

For assignments, please see the "Author" column below (highlighted blue).

If empty (no name is present), please volunteer to create content for that disease!

To volunteer, please [Contact us] with your page of interest.

WHO Classification of Head and Neck Tumours (5th Edition) Content
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes
Hereditary papillary renal carcinoma (MET) Disease
Multiple endocrine neoplasia type 2 (RET) Disease
Juvenile polyposis syndrome (BMPR1A, SMAD4) Disease
Hereditary neuroblastoma (ALK, PHOX2B) Disease
Encephalocraniocutaneous lipomatosis (FGFR1) Disease
Glucagon cell hyperplasia and neoplasia (GCGR) Disease
McCune-Albright syndrome (GNAS) Disease
Sturge-Weber syndrome (GNAQ) Disease
Neurofibromatosis type 1 (NF1) Disease
NF2-related schwannomatosis (NF2) Disease
Costello syndrome (HRAS) Disease
Noonan syndrome (Various genes) Disease
Schimmelpenning-Feuerstein-Mims (HRAS, KRAS) Disease
Carney complex (PRKAR1A, PDE8B, PDE11A) Disease
PROS syndrome (PIK3CA) Disease
Familial adenomatous polyposis (APC) Disease
Gastric Adenocarcinoma and Proximal Polyposis of Stomach - GAPPS (APC promoter) Disease
AXIN2-associated polyposis (AXIN2) Disease
Serrated polyposis (RNF43) Disease
WT1 related tumour predisposition syndrome (WT1) Disease
WAGR syndrome (WT1) Disease
Multiple endocrine neoplasia type 1 (MEN1) Disease
Peutz-Jeghers syndrome (STK11) Disease
Hereditary gastric and breast cancer syndrome (CDH1, CTNNA1) Disease
Hereditary mixed polyposis syndrome (GREM1) Disease
Naevoid basal cell carcinoma syndrome - Gorlin syndrome (PTCH1, SUFU, GPR161) Disease
SMO-related Curry-Jones syndrome (SMO) Disease
ELP1-related medulloblastoma predisposition syndrome(ELP1) Disease
Osteochondromatosis (EXT1, EXT2) Disease
Brooke-Spiegler syndrome (CYLD) Disease
Tuberous sclerosis (TSC1, TSC1) Disease
PTEN hamartoma tumour syndrome (PTEN) Disease
Activated Phosphatidylinositol-3-OH kinase δ Syndrome - APDS (PIK3CD) Disease
Multiple endocrine neoplasia type 5, MAX related tumours (MAX) Disease
MAFA-related familial insulinomatosis (MAFA) Disease
Birt-Hogg-Dube syndrome (FLCN) Disease
Familial chordoma (TBXT) Disease
Hyperparathyroidism jaw tumour syndrome (CDC73) Disease
Von Hippel-Lindau syndrome (VHL) Disease
SDH-deficient tumour syndrome - Hereditary phaeochromocytoma-paraganglioma syndromes (SDHA, SDHB, SDHC, SDHD, SDHAF2) Disease
Hereditary leiomyomatosis and renal cell carcinoma syndrome (FH) Disease
Hereditary tyrosinaemia type 1 (FAH) Disease
Li-Fraumeni syndrome (TP53) Disease
Retinoblastoma syndrome (RB1) Disease
Multiple endocrine neoplasia type 4 (CDKN1B) Disease
CDKN2A-related tumour predisposition syndrome (CDKN2A) Disease
CDK4-related melanoma predisposition syndrome (CDK4) Disease
Autoimmune lymphoproliferative syndrome (FAS) Disease
Lynch Syndrome (MLH1, PMS2, MSH2, MSH6) Disease
Muir-Torre syndrome (MLH1, PMS2, MSH2, MSH6) Disease
Constitutional mismatch repair deficiency (CMMRD) syndrome (MLH1, PMS2, MSH2, MSH6) Disease
BRCA-related cancer predisposition syndrome (BRCA1, BRCA2) Disease
PALB2-related cancer predisposition syndrome (PALB2) Disease
RAD51-related cancer predisposition syndrome (RAD51C, RAD51D) Disease
Fanconi anaemia (FANC genes) Disease
MUTYH-associated polyposis (MUTYH) Disease
NTHL1-related tumour syndrome (NTHL1) Disease
MBD4-associated neoplasia syndrome (MBD4) Disease
Xeroderma Pigmentosum Disease
Ataxia-telangiectasia syndrome (ATM) Disease
CHEK2-related hereditary (breast) cancer predisposition syndrome (CHEK2) Disease
Nijmegen breakage syndrome (NBN) Disease
Polymerase proofreading-associated polyposis (POLD1, POLE) Disease
Bloom syndrome (BLM) Disease
Werner syndrome (WRN) Disease
Rothmund-Thomson syndrome (ANAPC1, RECQL4) Disease
DDX41-related haematologic tumour predisposition syndrome (DDX41) Disease
Mosaic variegated aneuploidy (BUB1B, CEP57, TRIP13, BUB1, BUB3) Disease
Klinefelter syndrome Disease
Turner syndrome Disease
Down syndrome Disease
Dyskeratosis congenita (DKC1, TERT, TERC, TINF2, Other IBMFS genes) Disease
POT1 and Shelterin-related tumour predisposition syndrome (POT1, ACD, TERF2IP, TERT promoter) Disease
Beckwith-Wiedemann spectrum (IGF2; CDKN1C) Disease
Enchondromatosis (IDH1, IDH2) Disease
Rhabdoid tumour predisposition syndrome (SMARCB1, SMARCA4) Disease
Schwannomatosis (SMARCB1, LZTR1) Disease
Clear cell meningioma predisposition syndrome (SMARCE1) Disease
Weaver syndrome (EZH2) Disease
DICER1-related tumour predisposition syndrome (DICER1) Disease
MicroRNA processor tumour predisposition syndromes (DROSHA, DGCR8) Disease
Goldenhar syndrome (MYT1, SF3B2) Disease
BAP1-related tumour predisposition syndrome (BAP1) Disease


Retrieved from "https://ccga.io/index.php?title=HAN5:Volunteer_Assignments_and_Opportunities&oldid=14252"